Cynata Therapeutics' (ASX:CYP) lead asset, CYP-001, could see an upward revision in its pricing assumptions if the launch of Mesoblast's (ASX:MSB) Ryoncil sets a high market precedent, according to a Feb.10 note by Euroz Hartleys.
Based on estimates, Ryoncil could be priced between $500,000 and over US$1 million per patient.
Given that Ryoncil is the first US Food and Drug Administration-approved mesenchymal stem cell (MSC) therapy, its pricing may influence similar treatments, including CYP-001, Euroz added.
Euroz Hartleys notes that while CYP-001, is unlikely to match Ryoncil's pricing, a price of $1 million per patient for Ryoncil could prompt an upward revision of CYP-001's current price estimate of $150,000 per patient.
It maintained CYP's speculative buy rating and $0.67 price target.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。